Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
PNT POINT Biopharma
8.000+0.590+7.96%
Close
01/31 16:00 ET
8.0000.0000.00%
Post Mkt Price 01/31 16:04 ET
High
8.050
Open
7.420
Turnover
4.49M
Low
7.420
Pre Close
7.410
Volume
567.15K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
POINT Biopharma Global (NASDAQ:PNT) Shares Up 6.5%
Shares of POINT Biopharma Global Inc. (NASDAQ:PNT – Get Rating) shot up 6.5% during trading on Tuesday . The company traded as high as $7.96 and last traded at $7.89. 140,575 shares traded hands duri
Pieris Pharmaceuticals (NASDAQ:PIRS) Vs. POINT Biopharma Global (NASDAQ:PNT) Financial Analysis
Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) and POINT Biopharma Global (NASDAQ:PNT – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Aurinia Pharmaceuticals (AUPH) and POINT Biopharma Global (PNT)
POINT Biopharma Completes Enrollment in Phase 3 Trial of PNT2002 to Treat Prostate Cancer; Shares Rise
POINT Biopharma Completes Randomization In PNT2002's Phase 3 SPLASH Trial
POINT Biopharma Completes Randomization In PNT2002's Phase 3 SPLASH Trial
Top Premarket Decliners
07:43 AM EST, 01/09/2023 (MT Newswires) -- Daktronics (DAKT) shares sank 22%, reversing from Friday's gains. POINT Biopharma (PNT) shares tumbled 20% following a 1.7% gain from the previous session. S
POINT Biopharma Global Inc.'s (NASDAQ:PNT) Path To Profitability
With the business potentially at an important milestone, we thought we'd take a closer look at POINT Biopharma Global Inc.'s (NASDAQ:PNT) future prospects. POINT Biopharma Global Inc., a radiopharmac
Point Biopharma, Lantheus Close Licensing Deals for Cancer Treatment Candidates
10:43 AM EST, 12/20/2022 (MT Newswires) -- Point Biopharma Global (PNT) and Lantheus (LNTH) said Tuesday that they have closed their strategic collaboration agreements wherein Lantheus will license ex
POINT Biopharma Announces Closing of Agreements With Lantheus Holdings
Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 With POINT Biopharma
NORTH BILLERICA, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial
Company Overview
More
POINT Biopharma Global, Inc. is a precision oncology company, which engages in the development and commercialization of radiopharmaceuticals for the treatment of cancer. It offers CanSEEK, a technology which aims to minimize radiopharmaceutical toxicity caused by off-target delivery by only activating a radiopharmaceuticals' targeting moiety. The company was founded by Joe McCann and Neil E. Fleshner on April 15, 2020 and is headquartered in Indianapolis, IN.
CEO： Dr. Joe McCann, PhD
Market： NASDAQ
Listing Date： 07/08/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet